Corporate Analysis: Sarepta Therapeutics and Market Context

Market Performance Snapshot

Sarepta Therapeutics (ticker SRPT) closed the trading day at a 3.68 % increase, reaching USD 19.17 per share as of 05:42 AM Central European Time on Wednesday, 21 March. The firm’s shares are widely available, with a total supply of 105.8 million outstanding. Over the last 24 hours, the combined trading volume amounted to USD 41.3 million.

In the broader context, Sarepta’s market capitalization stands at USD 1.8 billion. The company’s 200‑day simple moving average (SMA) sits slightly below its current price at USD 18.89. Over the past year, the stock peaked at USD 24.68 on 26 January 2026 and hit a low of USD 14.68 on 11 June 2026. Since the end of the previous month, the share price has declined by 11.97 %.

Peer Activity in the 24‑Hour Window

The day’s market movements also impacted several peer companies in the biotech and technology sectors:

  • Celldex Therapeutics (CLDX): Up 7.77 %, trading at USD 30.29, with a market cap of USD 2.2 billion.
  • Cleanspark (CLSK): Up 0.71 %, trading at USD 8.43, market cap USD 2.2 billion.
  • Netlist (NLST): Down 2.88 %, trading at USD 5.86, market cap USD 2.2 billion. Its price‑to‑earnings ratio is 2,234.62.
  • Enterprise Service (EFSC): Down 0.74 %, trading at USD 60.55, market cap USD 2.2 billion. P/E ratio stands at 11.88.
  • Viridian Therapeutics (VRDN): Up 9.30 %, trading at USD 22.43, market cap USD 2.2 billion.

These movements illustrate a mixed landscape, with some peers gaining momentum while others face temporary retracements.

Company Overview

Sarepta Therapeutics, Inc. is a biopharmaceutical firm that focuses on the discovery and development of RNA‑based therapeutics targeting rare and infectious diseases. The company positions itself as a pioneer in biotechnology, aiming to transform treatments for conditions that have historically received limited attention. Its product pipeline and global reach underscore its commitment to addressing unmet medical needs worldwide.

This article synthesizes the latest trading data and contextual market trends to provide a comprehensive view of Sarepta Therapeutics’ current standing and its peers’ performance within the biopharmaceutical sector.